China-based Vertex has announced receiving medical device approval from the National Medical Products Administration (NMPA) for its MoDAS (Movement Dysfunction Assessment Software) system. This marks a significant milestone as MoDAS is the first-in-class AI-based movement dysfunction assessment software globally.
MoDAS: AI-Powered Movement Disorder Assessment
MoDAS is an artificial intelligence/machine learning (AI/ML)-powered software used as a medical device (SaMD) that reviews videos from smart mobile devices to capture a patient’s movement status. The technology provides decision support for doctors in diagnosing movement disorders such as Parkinson’s disease. In a multi-center clinical study conducted in Shanghai, MoDAS’s recommendations were highly consistent with clinicians’ diagnoses based on existing criteria.
Company Background and Future Outlook
Founded in 2018, Vertex focuses on digital therapies for brain disorders under the brand Nervtex. The NMPA approval is a major milestone for the company, which aims to expand its product globally. This approval underscores Vertex’s commitment to leveraging AI technology to improve the diagnosis and treatment of movement disorders.-Fineline Info & Tech
